[go: up one dir, main page]

WO2008140595A3 - Haptènes trivalents synthétiques, complexes de ceux-ci et utilisations de ceux-ci - Google Patents

Haptènes trivalents synthétiques, complexes de ceux-ci et utilisations de ceux-ci Download PDF

Info

Publication number
WO2008140595A3
WO2008140595A3 PCT/US2007/086163 US2007086163W WO2008140595A3 WO 2008140595 A3 WO2008140595 A3 WO 2008140595A3 US 2007086163 W US2007086163 W US 2007086163W WO 2008140595 A3 WO2008140595 A3 WO 2008140595A3
Authority
WO
WIPO (PCT)
Prior art keywords
complexes
molecules
trivalent
haptens
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/086163
Other languages
English (en)
Other versions
WO2008140595A2 (fr
Inventor
Zihni Basar Bilgicer
Demetri T Moustakas
George M Whitesides
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of WO2008140595A2 publication Critical patent/WO2008140595A2/fr
Publication of WO2008140595A3 publication Critical patent/WO2008140595A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne des molécules d'haptène trivalent (molécules trihaptène) et des complexes de celles-ci. Les molécules d'haptène trivalent sont utiles pour la formation de complexes relativement stables comprenant des molécules d'haptène et des ligands divalents (par exemple, anticorps) pour les molécules d'haptène. De telles molécules trihaptène sont utiles pour des dosages, par exemple, d'anticorps, ou pour appauvrir un ligand d'un échantillon, par exemple, pour traiter une maladie par liaison d'un récepteur indésirable tel qu'un anticorps. Des complexes de molécules d'haptène trivalent sont utiles pour un ciblage sélectif de présentations multivalentes d'haptènes, à densité relativement élevée, tel qu'il se produit sur des cellules surexprimant une molécule sur leurs surfaces, telles que des cellules cancéreuses.
PCT/US2007/086163 2006-12-01 2007-11-30 Haptènes trivalents synthétiques, complexes de ceux-ci et utilisations de ceux-ci Ceased WO2008140595A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87237406P 2006-12-01 2006-12-01
US60/872,374 2006-12-01

Publications (2)

Publication Number Publication Date
WO2008140595A2 WO2008140595A2 (fr) 2008-11-20
WO2008140595A3 true WO2008140595A3 (fr) 2009-05-14

Family

ID=40002813

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/086163 Ceased WO2008140595A2 (fr) 2006-12-01 2007-11-30 Haptènes trivalents synthétiques, complexes de ceux-ci et utilisations de ceux-ci

Country Status (1)

Country Link
WO (1) WO2008140595A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124743B2 (en) 2006-06-01 2012-02-28 President And Fellows Of Harvard College Purification of a bivalently active antibody using a non-chromatographic method
US20160175458A1 (en) 2014-12-19 2016-06-23 Alkermes, Inc. Single chain fc fusion proteins
JP7084881B2 (ja) 2016-06-22 2022-06-15 アルカームス インコーポレーテッド Ｉｌ－１０の免疫刺激特性および抗炎症特性を調節するための組成物および方法
MA57908B1 (fr) 2019-11-25 2025-09-30 Alkermes, Inc. Composés macrocycliques substitués et méthodes de traitement associées
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4120954A (en) * 1977-04-04 1978-10-17 American Cyanamid Company 2,2',2"-[S-Phenenyltris(carbonylimino) ]tris-2-deoxy-D-glucopyranose and salts thereof
WO1997019106A2 (fr) * 1995-11-17 1997-05-29 The Regents Of The University Of California Structures contenant des residus peptoides de type collagene
WO2003074148A1 (fr) * 2002-02-28 2003-09-12 Rensselaer Polytechnic Institute Agents de deplacement de faible masse moleculaire, de haute affinite, pour chromatographie d'echange d'ions
WO2003097587A2 (fr) * 2002-05-22 2003-11-27 Applied Nanosystems B.V. Agents gelifiants
WO2005073240A2 (fr) * 2004-01-29 2005-08-11 Vysoká skola chemicko-technologická v Praze Nouveaux inhibiteurs de proteases du vih

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4120954A (en) * 1977-04-04 1978-10-17 American Cyanamid Company 2,2',2"-[S-Phenenyltris(carbonylimino) ]tris-2-deoxy-D-glucopyranose and salts thereof
WO1997019106A2 (fr) * 1995-11-17 1997-05-29 The Regents Of The University Of California Structures contenant des residus peptoides de type collagene
WO2003074148A1 (fr) * 2002-02-28 2003-09-12 Rensselaer Polytechnic Institute Agents de deplacement de faible masse moleculaire, de haute affinite, pour chromatographie d'echange d'ions
WO2003097587A2 (fr) * 2002-05-22 2003-11-27 Applied Nanosystems B.V. Agents gelifiants
WO2005073240A2 (fr) * 2004-01-29 2005-08-11 Vysoká skola chemicko-technologická v Praze Nouveaux inhibiteurs de proteases du vih

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
BILGIÇER BASAR ET AL: "A synthetic trivalent hapten that aggregates anti-2,4-DNP IgG into bicyclic trimers.", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 129, no. 12, March 2007 (2007-03-01), pages 3722 - 3728, XP002509074 *
CORBELL J B ET AL: "A comparison of biological and calorimetric analyses of multivalent glycodendrimer ligands for concanavalin A", TETRAHEDRON ASYMMETRY, vol. 11, no. 1, 2000, pages 95 - 111, XP004202373 *
FUJII H ET AL: "ANTIMETASTATIC ACTVITIES OF SYNTHETIC ARG-GLY-ASP-SER (RGDS) AND ARG-LEU-ASP-SER (RLDS) PEPTIDE ANALOGUES AND THEIR INHIBITORY MECHANISMS", BIOLOGICAL & PHARMACEUTICAL BULLETIN, vol. 18, no. 12, 1995, pages 1681 - 1688, XP001108987 *
JAYARAMAN N ET AL: "Synthesis of Carbohydrate-Containing Dendrimers. 5. Preparation of Dendrimers Using Unprotected Carbohydrates", TETRAHEDRON LETTERS, vol. 38, no. 38, 1997, pages 6767 - 6770, XP004091785 *
LEUNG D K ET AL: "Synthesis and binding properties of cyclodextrin trimers", TETRAHEDRON LETTERS, vol. 42, no. 36, 2001, pages 6255 - 6258, XP004302922 *
LOU X ET AL: "Radical cation formation in characterization of novel C3-symmetric disks and their precursors by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.", JOURNAL OF MASS SPECTROMETRY, vol. 41, no. 5, May 2006 (2006-05-01), pages 659 - 669, XP002509072 *
MÜLLER P ET AL: "Tethering of long-chain amino acids to a rigid aromatic core - A new type of preorganized surfactants acting as flotative agents", JJOURNAL OF SURFACTANTS AND DETERGENTS, vol. 4, no. 4, 2001, pages 407 - 414, XP002509073 *
MULLER P U ET AL: "Novel amphiphiles with preorganized functionalities-formation of Langmuir-films and efficiency in mineral flotation", ADVANCES IN COLLOID AND INTERFACE SCIENCE, vol. 114-115, 2005, pages 291 - 302, XP004925993 *
PEDRO A AND LEHMANN F: "Conformations of highly hindered aryl ethers - XVIII", TETRAHEDRON, vol. 30, 1974, pages 719 - 726, XP002509069 *
RAO J ET AL: "A trivalent system from vancomycin-D-Ala-D-Ala with higher affinity than avidin-biotin", SCIENCE, vol. 280, no. 5364, 1998, pages 708 - 711, XP002960537 *
RAO J ET AL: "Design, synthesis, and characterization of a high-affinity trivalent system derived from vancomycin and L-Lys-D-Ala-D-Ala", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 122, no. 12, 2000, pages 2698 - 2710, XP002509070 *
SUN SHUGUANG ET AL: "Thermodynamic studies on the recognition of flexible peptides by transition-metal complexes.", INORGANIC CHEMISTRY, vol. 41, no. 6, 2002, pages 1584 - 1590, XP002509071 *

Also Published As

Publication number Publication date
WO2008140595A2 (fr) 2008-11-20

Similar Documents

Publication Publication Date Title
WO2008048970A3 (fr) Anticorps synthétiques
MX358410B (es) Anticuerpos humanos contra el ligando 4 de tipo delta humano.
WO2007106744A8 (fr) Anticorps anti-5t4 et leurs utilisations
WO2005086875A3 (fr) Anticorps t84.66 anti-ace humanise et ses applications
WO2008067547A3 (fr) Bibliothèques d'immunoglobulines améliorées
WO2007027713A3 (fr) Polypeptides et anticorps
WO2011094593A3 (fr) Nouveaux anticorps d'affinité moindre et procédés de fabrication associés
WO2006031653A3 (fr) Anticorps anti-5t4 humanises et conjugues anticorps anti-5t4/calicheamicine
WO2005023986A3 (fr) Micro-arn utilises comme ligands et molecules cibles
EP2348052A3 (fr) Internalisation d'anticorps monoclonaux humains ciblant des celles de cancer de la prostate in situ
AU2008257801A8 (en) RSV-specific binding molecules and means for producing them
WO2007129895A3 (fr) Anticorps monoclonal antagoniste anti-cd40 humain
WO2009140039A3 (fr) Anticorps synthétiques
WO2008098917A3 (fr) Nouveaux anticorps
NO20082524L (no) Biologisk materiale og anvendelse av samme
WO2008055080A3 (fr) Procédé pour le blocage d'une liaison à une protéine non spécifique sur une surface fonctionnalisée
WO2008140595A3 (fr) Haptènes trivalents synthétiques, complexes de ceux-ci et utilisations de ceux-ci
WO2010088522A3 (fr) Nouveaux anticorps à affinité réduire et applications associées
WO2008151819A3 (fr) Traitement de tumeurs à l'aide d'un anticorps anti-l1 spécifique
WO2007120766A3 (fr) Agonistes de récepteur d'érythropoïétine
WO2011064257A3 (fr) Réactifs polypeptidiques monospécifiques
WO2006002895A3 (fr) Compositions et methodes de liberation d'agents anti-tumoraux
WO2006034278A3 (fr) Procedes et compositions de detection du cancer au moyen de composants de la particule spliceosomale u2
EP3300739A3 (fr) Anticorps et molécules correspondantes se liant aux protéines 161p2f10b
WO2008081331A3 (fr) Amélioration du niveau d'expression d'anticorps par réingénierie de cadre

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07874329

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07874329

Country of ref document: EP

Kind code of ref document: A2